We have examined novel benzylhydroxylamine derivatives for their inhibitory effects on the replication of human immunodeficiency virus (HIV) in cell cultures. Among the series, O-(2-chloro-6-fluo-robenzyl)hydroxylamine (RD6-Y664) was found to be the most potent inhibitor of HIV-1. The EC50 for HIV-1 strain IIIB was 1.6 μg/ml with a selectivity index greater than 38 in MT-4 cells. It also inhibited the replication of other HIV strains including a nonnucleoside reverse transcriptase (RT) inhibitor-resistant mutant, a nucleoside RT inhibitor-resistant mutant and HIV-2, in acutely infected cells. However, the compound did not affect HIV-1 production in chronically infected cells. A time-of-addition experiment and detection of proviral DNA synthesis suggested that RD6-Y664 targeted an early step of the viral replication cycle, presumably a process prior to reverse transcription. In fact, an assay for HIV-1 RT revealed that the compound did not suppress enzyme activity. Furthermore, RD6-Y664 did not show any inhibition of gp120–CD4 interaction, or binding of anti-CXCR4 antibody to CXCR4.
BabaMShigetaSYuasaSTakashimaHSekiyaKUbasawaMTanakaHMiyasakaTWalkerRT & De ClercqE (1994) Preclinical evaluation of MKC-422, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrobiral Agents Chemotherapy38: 688–692.
2.
BauerHMTingYGreerCEChambersJCTashiroCJChimeraJReingoldA & ManosMM (1991) Genital human papillomavirus infection in female university students as determined by PCR-based method. Journal of the American Medical Association265: 472–477.
3.
ButeraSTPerezVLWuB-YNabelGJ & FolksTM (1991) Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection. Journal of Virology65: 4645–4653.
4.
ChouJ & ChouT-C (1986) Dose—effect analysis with microcomputers: Quantitation of ED50, LD50, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics. In Computer Software for IBM-PC and Manual, pp. 19–32. Cambridge; Elsevier-Biosoft.
5.
ChouT-C & TalalayP (1984) Quantitative analysis of dose—effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation22: 27–55.
6.
CohenJ (1997) The daunting challenge of keeping HIV suppressed. Science277: 32–33.
7.
CollierACCoombsRWSchoenfeldDABassettRLTimponeJBaruchAJonesMFaceyKWhitacreCMcAuliffeVJFriedmanHMMeriganTCReichmanRCHooperC & CoreyL, for the AIDS Clinical Trials Group (1996) Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. New England Journal of Medicine334: 1011–1017.
8.
De ClercqE (1995) Antiviral therapy for human immunodeficiency virus infections. Clinical Microbiology Reviews8: 200–239.
9.
FujiwaraMOkamotoMIjichiKTokuhisaKHanasakiYKatsuuraKUemuraDShigetaSKonnoKYokotaT and BabaM (1998) Upregulation of HIV-1 replication in chronically infected cells by ingenol derivatives. Archives of Virology143: 2003–2010.
10.
FurmanPAFyfeJASt ClairMHWeinholdKRideoutJLFreemanGALehrmanNusinoff SBolognesiDPBroderSMitsuyaH & BarryDW (1986) Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proceedings of the National Academy of Sciences, USA83: 8333–8337.
11.
GaoW-YJohnsDGChokekijchaiS & MitsuyaH (1995) Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA92: 8333–8337.
12.
GulickRMMellorsJWHavlirDEronJJGonzalezCMcMahonDRichmanDDValentineFTJonasLMeibohmAEminiEA & ChodakewitzJA (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine337: 734–739.
13.
HammerSMSquiresKEHughesMDGrimesJMDemeterLMCurrierJSEronJJJrFeinbergJEBalfourHHJrDeytonLRChodakewitzJA & FischlMA, for the AIDS Clinical Trials Group 320 Study Team (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine337: 725–733.
14.
HoDDNeumannAUPerelsonASChenWLeonardJM & MarkowitzM (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature373: 123–126.
15.
KikukawaRKoyanagiYHaradaSKobayashiNHatanakaM & YamamotoN (1986) Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line molt-4. Journal of Virology57: 1159–1162.
16.
KimptonJ & EmermanM (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. Journal of Virology66: 2232–2239.
17.
LipskyJJ (1996) Antiretroviral drugs for AIDS. Lancet348: 800–803.
18.
MooreJPTrkolaA & DragicT (1997) Co-receptors for HIV-1 entry. Current Opinion in Immunology9: 551–562.
19.
PauwelsRBalzariniJBabaMSnoeckRScholsDHerdewijnPDesmyterJ & De ClercqE (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virology Methods20: 309–321.
20.
ShirasakaTKavlickMFUenoTGaoW-YKojimaEAlcaideMLChokekijchaiSRoyBMArnoldEYarchoanR & MitsuyaH (1995) Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proceedings of the National Academy of Sciences, USA92: 2398–2402.
21.
WeiXGhoshSKTaylorMEJohnsonVAEminiEADeutschPLifsonJDBonhoefferSNowakMAHahnBHSaagMS & ShawGM (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature373: 117–122.
22.
YuasaSSadakataYTakashimaHSekiyaKInouyeNUbasawaM & BabaM (1993) Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a nonnucleoside inhibitor, MKC-442. Molecular Pharmacology44: 895–900.
